Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III,Multi-Center,Randomized,Double-blind,Active-Controlled Trial to Compare the Efficacy , Safety and Immunogenicity of MW05 and PEG-rhG-CSF in Prophylactic Treatment for Chemotherapy-Induced Neutropenia

Next Previous
X
Search
Trial Profile

A Phase II/III,Multi-Center,Randomized,Double-blind,Active-Controlled Trial to Compare the Efficacy , Safety and Immunogenicity of MW05 and PEG-rhG-CSF in Prophylactic Treatment for Chemotherapy-Induced Neutropenia

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 8MW 0511 (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Pegfilgrastim
  • Indications Chemotherapy-induced damage; Febrile neutropenia; Neutropenia
  • Focus Therapeutic Use
  • Sponsors Mabwell (Shanghai) Bioscience

    • Most Recent Events

    • 19 Dec 2023 According to Mabwell media release, based on results from this trial the National Medical Products Administration (NMPA) has approved new drug application of 8MW0511.
    • 25 Oct 2023 According to Mabwell media release, data from this trial were presented at ESMO Congress 2023.
    • 25 Oct 2023 Results presented in the Mabwell media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top